Testing anakinra to reduce inflammation in pediatric sepsis MODS
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Digestive system, Heart & circulation, Immune system & allergy, Infections, Kidney & urinary, Lungs & breathing clinical trials.
This study tests whether a medicine called anakinra can “turn down” harmful inflammation in children with severe illness from sepsis. It aims to improve organ function when multiple organs are starting to fail.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 years old (and not born too early; at least 40 weeks corrected age)
- You are currently in the PICU or CICU (intensive care for very sick patients)
- In the last 3 days, at least two new organ problems have appeared after the sepsis started
- There is a known or suspected infection that triggered the sepsis
- Your weight is 3 kg or more
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called anakinra that may reduce heart swelling in children with a severe heart condition called acute myocarditis. It might help their heart recover faster while they are in the intensive care unit.
This trial is testing several different treatments to find the best one for each person with sepsis. It looks at specific 'treatable traits' like inflammation, blood clotting problems, or immune system issues to match you with the right therapy. The goal is to improve recovery and survival.
This study tests whether anakinra, a medicine that calms inflammation, is just as good as the standard treatment for Kawasaki disease in children. The goal is to reduce fever and prevent heart problems.
This study compares two treatments—anakinra and IVIG—for children with Kawasaki disease who still have fever after their first standard IVIG treatment. It aims to find which option works better and is safer for “IVIG non-responders” who may be at risk for heart complications.
This trial studies how a specific pattern in blood (called “molecular fingerprinting”) changes in children with suspected or developing sepsis. The goal is to help doctors better recognize sepsis early and understand how it progresses, which may improve care.
This trial tests different doses and ways of giving a medicine called anakinra to preterm babies. It aims to find the safest and most effective dose to help reduce inflammation.
Hear when a new Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.